residual tumor treatment in mutant brca-1 triple-negative breast cancer
Published 9 months ago • 251 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
0:43
management of residual disease in triple negative breast cancer
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
0:57
treating brca1 and brca2 breast cancer
-
4:24
the latest treatment options for brca-mutated breast cancer
-
1:16
tackling residual disease in breast cancer
-
5:47
the meaning of residual disease in breast cancer
-
5:15
brca-mutated triple-negative breast cancer
-
28:57
2021 force | hereditary cancer | cancer risks, screening & prevention for brca1 or brca2 mutations
-
2:21
profiling of brca mutations in colorectal cancer
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
1:26
hormone receptor status and tumor subtypes in brca-variant breast cancer
-
6:19
chemosymposium 2011: parp treatment for brca mutated and triple negative breast cancer
-
6:04
germline brca mutations in tnbc
-
1:52
parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer
-
3:39
zen-3694, a novel bet inhibitor, in tnbc without germline brca1/2 mutations
-
2:37
triple-negative breast cancer patients should undergo genetic screening - mayo clinic
-
2:05
treatment advances in tnbc
-
1:17
dr. traina on parp inhibition in brca-mutated breast cancer
-
5:18
parp inhibitors for brca-mutated tnbc